Prognostic value of seminal vesicle involvement due to prostate cancer in radical prostatectomy specimens

被引:5
作者
Algarra, R. [1 ]
Barba, J. [1 ]
Merino, I. [1 ]
Tienza, A. [1 ]
Tolosa, E. [1 ]
Robles, J. E. [1 ]
Zudaire, J. [1 ]
机构
[1] Univ Navarra Clin, Dept Urol, Pamplona, Spain
来源
ACTAS UROLOGICAS ESPANOLAS | 2015年 / 39卷 / 03期
关键词
Prostate cancer; Biochemical progression; Prostate specific antigen; Gleason; Rescue therapy; ANDROGEN ABLATION THERAPY; HORMONAL-THERAPY; ANTIGEN; PROGRESSION; CARCINOMA; RADIATION; SURVIVAL; RISK; ADENOCARCINOMA; INVASION;
D O I
10.1016/j.acuro.2014.05.009
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To study the influence, in terms of prognosis, of the finding of seminal vesicle involvement in patients with prostate adenocarcinoma treated with radical prostatectomy. Material and method: We reviewed a series of patients with seminal vesicle involvement with clinically localized prostate adenocarcinoma who underwent radical prostatectomy between 1989 and 2009, focusing on their clinical-pathological characteristics, biochemical progression-free survival (BPFS) and specific survival (SS). We assessed the variables that influenced BPFS and designed a risk model. Results: A total of 127 out of 1,132 patients who underwent surgery (11%) presented seminal vesicle invasion (i.e., pT3b). In the multivariate study of the entire series (Cox model), pT3b affects the BPFS (HR: 2; 95% CI: 1.4-3.3; P=.001). Other influential factors were the affected borders, initial prostate-specific antigen levels, pathological Gleason score and the presence of palpated tumor. The pT3b tumors have poorer clinical-pathological variables when compared with pT2 and pT3a tumors. Sixty-five percent of the patients evidenced biochemical progression. The BPFS was significantly poorer for pT3b (40 +/- 4% and 28 4% at 5 and 10 years, respectively) than for pT2 and pT3a (P<.0001). The SS was also poorer in patients with pT3b tumors (91 +/- 2% and 76 +/- 4% at 5 and 10 years, respectively) (P<.0001). The predictors within the pT3b patient group were: PSA levels >10 ng/mL (HR: 1.9; 95% CI: 1.04-3.6; P=.04) and pathological Gleason score 8-10 (HR: 2.1; 95% CI: 1.2-3.5; P=.03). We designed a risk model that accounts for the variables involved, which entails 2 groups with different BPFS (P=.004): Group 1 (0-1 variable), with a BPFS of 46 +/- 7% and 27 +/- 8% at 5 and 10 years, respectively; and Group 2 (2 variables), with a BPFS of 14 +/- 7% and 5 +/- 5% at 5 and 10 years, respectively. Conclusion: Seminal vesicle involvement severely and negatively affects the BPFS and SS. We designed a risk model with the independent influential variables in BPFS (pathological Gleason score 8-10 and PSA levels >10 ng/mL). This model confirms that pT3b tumors are a heterogeneous group, which includes an important group with better prognosis when surgical treatment is performed. (C) 2014 AEU. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:144 / 153
页数:10
相关论文
共 44 条
[1]   Course of the Type of Patient who is Candidate for Radical Prostatectomy Over 2 Decades (1989-2009) [J].
Algarra, R. ;
Zudaire, J. ;
Rosell, D. ;
Robles, J. E. ;
Berian, J. M. ;
Pascual, I. .
ACTAS UROLOGICAS ESPANOLAS, 2013, 37 (06) :347-353
[2]   Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? [J].
Amling, CL ;
Bergstralh, EJ ;
Blute, ML ;
Slezak, JM ;
Zincke, H .
JOURNAL OF UROLOGY, 2001, 165 (04) :1146-1151
[3]  
Bastide C, 2012, BJU INT, V109, P525, DOI 10.1111/j.1464-410X.2011.10332.x
[4]   Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy [J].
Blute, ML ;
Bergstralh, EJ ;
Iocca, A ;
Scherer, B ;
Zincke, H .
JOURNAL OF UROLOGY, 2001, 165 (01) :119-125
[5]  
BYAR DP, 1973, CANCER, V32, P1126, DOI 10.1002/1097-0142(197311)32:5<1126::AID-CNCR2820320518>3.0.CO
[6]  
2-C
[7]  
Byar DP, 1998, NATL CANCER I MONOGR, P165
[8]  
Cheng L, 2001, CANCER-AM CANCER SOC, V91, P66, DOI 10.1002/1097-0142(20010101)91:1<66::AID-CNCR9>3.0.CO
[9]  
2-P
[10]   The changing face of prostate cancer [J].
Cooperberg, MR ;
Moul, JW ;
Carroll, PR .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (32) :8146-8151